justbacked

Biopharma, Life Science, Therapeutics

City Therapeutics

City Therapeutics raised $99.5M in a Series B announced on Jun 8, 2026, led by ARCH Venture Partners, Fidelity, Sofinnova Investments, Invus, AN Ventures. Since then it has posted 18 roles (11 still open), the first 36 days after it. Another 3 open roles were posted before the announcement. With 14 open roles it is hiring more than 42% of the 121 Series B startups on JustBacked (median: 15). In total it has raised $235M over 2 rounds from 11 investors.

Roles posted per month since the round
  • July 20263
  • August 20262
  • September 20263
  • October 20264
  • November 20266

From City Therapeutics's own hiring system, by posting date. Tracked since Aug 21, 2026; roles that closed before then aren't counted.

City Therapeutics is a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines for a range of diseases.

Why join City Therapeutics?

If RNAi drugs reach the eye, nervous system and fat tissue, not just the liver, a whole drug class gets a far wider reach. City Therapeutics, a Cambridge, Massachusetts biotech founded by RNAi pioneers, is building that platform on a $100M Series B that beat about 75% of comparable rounds. With $235M raised and ARCH Venture Partners and Fidelity behind it, five open roles show where the money goes next.

JustBacked's take, based on City Therapeutics's own site and its funding and hiring data.

Series B · $99.5M · 166d agocitytx.com

Hiring velocity

Open roles
14
Added, 30 days
+7
Added, 7 days
+6
Closed, 30 days
1
Raised
166 days ago
Led by
ARCH Venture Partners, Fidelity, Sofinnova Investments, Invus, AN Ventures
Team size
101-250
HQ
Cambridge, Massachusetts, United States
Newest role
1d ago
Tracked since
Aug 21, 2026

Where they're hiring

Clinical3
Science2
Operations2
Legal1
Hardware1
Marketing1

Open roles at City Therapeutics

Source: citytx.com, checked daily.